Pharma Mar Management
Management Kriterienprüfungen 2/4
Pharma Mar CEO ist Jose Fernandez Sousa-Faro , ernannt in Jan 1986, hat eine Amtszeit von 40.42 Jahren. besitzt direkt 6.43% der Aktien des Unternehmens, im Wert von €81.51M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 15.3 Jahre bzw. 4 Jahre.
Wichtige Informationen
Jose Fernandez Sousa-Faro
Geschäftsführender
n/a
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | 40.4yrs |
| Eigentum des Geschäftsführers | 6.4% |
| Durchschnittliche Amtszeit des Managements | 15.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Jun 25
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.Narrativ-Update • Jun 06
PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).Narrativ-Update • May 21
PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Analyseartikel • May 09
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...Analyseartikel • Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Analyseartikel • Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Analyseartikel • Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Analyseartikel • Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Analyseartikel • May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
Neues Narrativ • Mar 09
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.Analyseartikel • Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...Analyseartikel • Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Analyseartikel • Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Analyseartikel • Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Analyseartikel • Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Analyseartikel • May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Analyseartikel • Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...Analyseartikel • Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Analyseartikel • Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Market forces rained on the parade of Pharma Mar, S.A. ( BME:PHM ) shareholders today, when the analysts downgraded...Geschäftsführer
Jose Fernandez Sousa-Faro
40.4yrs
Amtszeit
€294,000
Vergütung
Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 40.4yrs | €294.00k | 6.43% € 81.5m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 7.4k | |
| Founder | no data | keine Daten | keine Daten | |
| Chief Financial Officer | 26.4yrs | keine Daten | keine Daten | |
| Head of Capital Markets & Investor Relations | 11.4yrs | keine Daten | keine Daten | |
| General Counsel & Secretary of the Board of Directors | 6.8yrs | keine Daten | keine Daten | |
| Global Compliance Head | 6.1yrs | keine Daten | keine Daten | |
| Communication Director | no data | keine Daten | keine Daten | |
| Director of Corporate Development | 4.4yrs | keine Daten | keine Daten | |
| Director of Human Resources & IT | 22.9yrs | keine Daten | keine Daten | |
| Managing Director of Oncology & Virology Business Units | 19.2yrs | keine Daten | keine Daten | |
| Senior Vice President of Strategic Development | no data | keine Daten | keine Daten |
15.3yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrenes Management: Das Managementteam von PHM ist erfahren und erfahren (durchschnittliche Amtszeit von 15.3 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | no data | €294.00k | 6.43% € 81.5m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 7.4k | |
| Independent Other External Director | 5.4yrs | €35.00k | 0.062% € 788.4k | |
| Independent Other External Director | no data | €35.00k | keine Daten | |
| Proprietary Director | no data | €34.00k | 5.52% € 69.9m | |
| Independent Director | 7.4yrs | keine Daten | 0.010% € 131.4k | |
| Representative Proprietary Director | 5.5yrs | keine Daten | keine Daten | |
| Independent Director | 4yrs | keine Daten | 0.010% € 131.4k | |
| Independent Coordinating Director | 4yrs | keine Daten | keine Daten | |
| Independent Director | 4yrs | keine Daten | keine Daten | |
| Independent Other External Director | no data | keine Daten | 0.010% € 131.4k | |
| Independent Director | 3.1yrs | keine Daten | keine Daten |
4.0yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrener Vorstand: PHMDie Vorstandsmitglieder gelten als erfahren (4 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/26 00:30 |
| Aktienkurs zum Tagesende | 2026/06/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Pharma Mar, S.A. wird von 12 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |